Musical chairs at Amgen and Roche
USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech company, says that Kevin Sharer, its chairman and chief executive since 2000, plans to retire from the company at the end of 2012, following 20 years of service with the firm.
To facilitate an orderly transition process, Mr Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the company's board of directors until December 31, 2012, at which time he will retire altogether. Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012. It is the intention of the Board of Directors to elect Mr Bradway chairman at the end of 2012.
In addition, Roger Perlmutter will retire as executive vice president of R&D effective February 12, 2012. Dr Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013. Dr Perlmutter joined Amgen in 2000
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze